[1]
. Correction: Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Annals of the rheumatic diseases. 2017 Sep:76(9):1634. doi: 10.1136/annrheumdis-2016-210094corr1. Epub
[PubMed PMID: 28798079]
[2]
Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology : JEADV. 2019 May:33(5):850-856. doi: 10.1111/jdv.15489. Epub 2019 Apr 10
[PubMed PMID: 30762909]
Level 1 (high-level) evidence
[3]
Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Rouphael NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH, ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. The New England journal of medicine. 2021 Mar 4:384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11
[PubMed PMID: 33306283]
[4]
Rubin R. Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment. JAMA. 2022 Jun 21:327(23):2281. doi: 10.1001/jama.2022.9846. Epub
[PubMed PMID: 35727290]
[5]
Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the Treatment of Alopecia Areata. Drugs. 2023 Jun:83(9):761-770. doi: 10.1007/s40265-023-01873-w. Epub 2023 May 17
[PubMed PMID: 37195491]
[6]
Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, King BA, Thyssen JP, Silverberg JI, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman-Yassky E, Beck LA, Janes JM, DeLozier AM, Gamalo M, Brinker DR, Cardillo T, Nunes FP, Paller AS, Wollenberg A, Reich K. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. The British journal of dermatology. 2020 Aug:183(2):242-255. doi: 10.1111/bjd.18898. Epub 2020 Mar 5
[PubMed PMID: 31995838]
Level 1 (high-level) evidence
[7]
Zhang J, Qi F, Dong J, Tan Y, Gao L, Liu F. Application of Baricitinib in Dermatology. Journal of inflammation research. 2022:15():1935-1941. doi: 10.2147/JIR.S356316. Epub 2022 Mar 18
[PubMed PMID: 35330989]
Level 2 (mid-level) evidence
[8]
Dong J, Huang X, Ma LP, Qi F, Wang SN, Zhang ZQ, Wei SN, Gao L, Liu F. Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro. Dose-response : a publication of International Hormesis Society. 2022 Apr-Jun:20(2):15593258221105370. doi: 10.1177/15593258221105370. Epub 2022 May 31
[PubMed PMID: 35663493]
Level 2 (mid-level) evidence
[9]
Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. Journal of the American Academy of Dermatology. 2017 Apr:76(4):736-744. doi: 10.1016/j.jaad.2016.12.005. Epub 2017 Jan 28
[PubMed PMID: 28139263]
[10]
Mogul A, Corsi K, McAuliffe L. Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis. The Annals of pharmacotherapy. 2019 Sep:53(9):947-953. doi: 10.1177/1060028019839650. Epub 2019 Mar 24
[PubMed PMID: 30907116]
[11]
Musumeci F, Greco C, Giacchello I, Fallacara AL, Ibrahim MM, Grossi G, Brullo C, Schenone S. An Update on JAK Inhibitors. Current medicinal chemistry. 2019:26(10):1806-1832. doi: 10.2174/0929867325666180327093502. Epub
[PubMed PMID: 29589523]
[12]
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R, BRAVE-AA Investigators. Two Phase 3 Trials of Baricitinib for Alopecia Areata. The New England journal of medicine. 2022 May 5:386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26
[PubMed PMID: 35334197]
[13]
Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. Journal of clinical pharmacology. 2014 Dec:54(12):1354-61. doi: 10.1002/jcph.354. Epub
[PubMed PMID: 24965573]
[14]
Huang F, Luo ZC. Risk of Adverse Drug Events Observed with Baricitinib 2 mg Versus Baricitinib 4 mg Once Daily for the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2018 Oct:32(5):415-423. doi: 10.1007/s40259-018-0304-3. Epub
[PubMed PMID: 30203252]
Level 1 (high-level) evidence
[15]
Honda S, Harigai M. The safety of baricitinib in patients with rheumatoid arthritis. Expert opinion on drug safety. 2020 May:19(5):545-551. doi: 10.1080/14740338.2020.1743263. Epub 2020 Mar 21
[PubMed PMID: 32174196]
Level 3 (low-level) evidence
[17]
Manoharan S, Ying LY. Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale. 2022:2022():8332819. doi: 10.1155/2022/8332819. Epub 2022 Aug 2
[PubMed PMID: 35938147]
Level 1 (high-level) evidence
[18]
Bieber T, Katoh N, Simpson EL, de Bruin-Weller M, Thaçi D, Torrelo A, Sontag A, Grond S, Issa M, Lu X, Cardillo T, Holzwarth K, Thyssen JP. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. The Journal of dermatological treatment. 2023 Dec:34(1):2161812. doi: 10.1080/09546634.2022.2161812. Epub
[PubMed PMID: 36546346]
[19]
Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. The New England journal of medicine. 2017 Feb 16:376(7):652-662. doi: 10.1056/NEJMoa1608345. Epub
[PubMed PMID: 28199814]
[20]
Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Annals of the rheumatic diseases. 2018 Jul:77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20
[PubMed PMID: 29463520]
[21]
Verden A, Dimbil M, Kyle R, Overstreet B, Hoffman KB. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors. Drug safety. 2018 Apr:41(4):357-361. doi: 10.1007/s40264-017-0622-2. Epub
[PubMed PMID: 29196988]
Level 3 (low-level) evidence
[22]
Posada MM, Cannady EA, Payne CD, Zhang X, Bacon JA, Pak YA, Higgins JW, Shahri N, Hall SD, Hillgren KM. Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. Clinical and translational science. 2017 Nov:10(6):509-519. doi: 10.1111/cts.12486. Epub 2017 Jul 27
[PubMed PMID: 28749581]
[23]
Winthrop KL, Harigai M, Genovese MC, Lindsey S, Takeuchi T, Fleischmann R, Bradley JD, Byers NL, Hyslop DL, Issa M, Nishikawa A, Rooney TP, Witt S, Dickson CL, Smolen JS, Dougados M. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Annals of the rheumatic diseases. 2020 Oct:79(10):1290-1297. doi: 10.1136/annrheumdis-2019-216852. Epub 2020 Aug 11
[PubMed PMID: 32788396]
[24]
Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nature reviews. Rheumatology. 2022 May:18(5):301-304. doi: 10.1038/s41584-022-00767-7. Epub 2022 Mar 22
[PubMed PMID: 35318462]
[25]
Maqsood MH, Weber BN, Haberman RH, Lo Sicco KI, Bangalore S, Garshick MS. Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis of Randomized Trials. ACR open rheumatology. 2022 Oct:4(10):912-922. doi: 10.1002/acr2.11479. Epub 2022 Jul 28
[PubMed PMID: 35903881]
Level 1 (high-level) evidence
[26]
Harigai M, Winthrop K, Takeuchi T, Hsieh TY, Chen YM, Smolen JS, Burmester G, Walls C, Wu WS, Dickson C, Liao R, Genovese MC. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD open. 2020 Feb:6(1):. doi: 10.1136/rmdopen-2019-001095. Epub
[PubMed PMID: 32098857]
[28]
Qiu C, Zhao X, She L, Shi Z, Deng Z, Tan L, Tu X, Jiang S, Tang B. Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Lipids in health and disease. 2019 Feb 18:18(1):54. doi: 10.1186/s12944-019-0994-7. Epub 2019 Feb 18
[PubMed PMID: 30777075]
Level 2 (mid-level) evidence
[29]
Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC, van Laar JM, de Thurah A, Landewé RB, Molto A, Müller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Annals of the rheumatic diseases. 2020 Jan:79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14
[PubMed PMID: 31413005]
[30]
Peng L, Stebbing J, Wang YJ. Reply to letter to the editor: baricitinib and toxicity is a rare occurrence. Expert opinion on drug safety. 2020 Oct:19(10):1371-1372. doi: 10.1080/14740338.2020.1812192. Epub 2020 Aug 24
[PubMed PMID: 32804556]
Level 3 (low-level) evidence